SLP
Simulations Plus, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Simulations Plus, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
No thesis.
Largest filed tie
0
filed ties
Simulations Plus, Inc.
18.49
−0.01 · −0.03%
post 18.49 0.00%
Annual filing, covered
10-K parsed · Dec 1 '25
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Dec 1 '25
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
−0.55%
vs ±6.1% implied · ×0.09
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
shaded = implied · ▲▼ = realized
Same SIC code · 6
Same SEC industry code: Leidos Holdings, Inc., GoDaddy Inc., Jack Henry & Associates Inc and 3 more; of Simulations Plus, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Leidos Holdings, Inc., GoDaddy Inc., Jack Henry & Associates Inc and 3 more; of Simulations Plus, Inc.'s 6 closest co-movers, none share that code.
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| First Light | $51.1M | 17.64% | +6.07% |
| BlackRockindex-like | $27.5M | 9.49% | +19.94% |
| First Eagle | $19.6M | 6.76% | +44.27% |
| Vanguardindex-like | $13.6M | 4.68% | +0.24% |
| Kennedy | $9.9M | 3.40% | +38.47% |
| Manager | Value | % base | |
|---|---|---|---|
| First Light | $51.1M | 17.64% | +6.07% |
| BlackRockindex-like | $27.5M | 9.49% | +19.94% |
| First Eagle | $19.6M | 6.76% | +44.27% |
| Vanguardindex-like | $13.6M | 4.68% | +0.24% |
| Kennedy | $9.9M | 3.40% | +38.47% |
Bull2
Bear2
Expected move
No implied move.